Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by West, T.
Right arrow Articles by Waubant, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by West, T.
Right arrow Articles by Waubant, E.
Related Collections
Right arrow Prognosis
Right arrow Multiple sclerosis
NEUROLOGY 2006;67:809-813
© 2006 American Academy of Neurology

Are initial demyelinating event recovery and time to second event under differential control?

T. West, BS, M. Wyatt, MS, A. High, AB, A. Bostrom, PhD and E. Waubant, MD, PhD

From the University of California San Francisco Multiple Sclerosis Center, San Francisco, CA.

Address correspondence and reprint requests to Dr. Emmanuelle Waubant, University of California San Francisco Multiple Sclerosis Center, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117; e-mail: emmanuelle.waubant{at}ucsf.edu

Background: Relapsing-remitting multiple sclerosis (RRMS) begins with an initial demyelinating event (IDE) that can be monosymptomatic, polysymptomatic, or polyregional. Failure to recover from the IDE is a known predictor of later development of disability. Factors that predict IDE recovery (outside optic neuritis) and time to second event are relatively unknown. The authors speculate that IDE recovery and time to second event are under separate biologic or genetic control, and as such, their clinical predictors are different.

Methods: Data on all UCSF MS clinic patients are entered prospectively into an ACCESS database. The authors identified all patients seen at the UCSF clinic within 1 year of their IDE. Expanded Disability Status Scale scores, functional system scores, and visual acuity were used to define IDE severity and recovery.

Results: The cohort included 186 patients (127 women, 59 men) with an average onset age of 34 ± 10 years with 150 whites (non-Hispanic), 15 African Americans, 11 Hispanics, eight Asians, and two unknown/unreported. Worse onset severity predicted worse IDE recovery (23.1% of the patients with severe onset vs 32.9% with moderate severity vs 56.4% with mild onset recovered completely, p < 0.001). Polyregional onset predicted poor recovery compared to monoregional onset (46.2% vs 14.4%, p < 0.001). Nonwhite patients were 2.48 times more likely than whites to experience a second episode within 1 year from onset (95% CI: 1.45 to 4.23, p < 0.001). Similarly, age younger than 30 years predicted higher risk of a second exacerbation (hazard ratio 1.92, 95% CI: 1.17 to 3.15, p = 0.010).

Conclusion: Initial demyelinating event recovery and time to second event may have distinct predictors. These findings suggest that recovery and time to second event might be under separate biologic control.


Supported by the Nancy Davis Foundation and an educational grant from Teva Neuroscience.

Disclosure: The authors report no conflicts of interest.

Received August 11, 2005. Accepted in final form May 4, 2005.




This article has been cited by other articles:


Home page
J. Neurol. Neurosurg. PsychiatryHome page
E M Mowry, S Deen, I Malikova, J Pelletier, P Bacchetti, and E Waubant
The onset location of multiple sclerosis predicts the location of subsequent relapses
J. Neurol. Neurosurg. Psychiatry, April 1, 2009; 80(4): 400 - 403.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
E. M. Mowry, M. Pesic, B. Grimes, S. Deen, P. Bacchetti, and E. Waubant
Demyelinating events in early multiple sclerosis have inherent severity and recovery
Neurology, February 17, 2009; 72(7): 602 - 608.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
A Gajofatto, P Bacchetti, B Grimes, A High, and E Waubant
Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis
Multiple Sclerosis, January 1, 2009; 15(1): 50 - 58.
[Abstract] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
S Deen, P Bacchetti, A High, and E Waubant
Predictors of the location of multiple sclerosis relapse
J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1190 - 1193.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
M. Leone, S. Bonissoni, L. Collimedaglia, F. Tesser, S. Calzoni, A. Stecco, P. Naldi, and F. Monaco
Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study
Multiple Sclerosis, May 1, 2008; 14(4): 485 - 493.
[Abstract] [PDF]


Home page
NeurologyHome page
J. R. Rinker II, K. Trinkaus, R. T. Naismith, and A. H. Cross
Higher IgG index found in African Americans versus Caucasians with multiple sclerosis
Neurology, July 3, 2007; 69(1): 68 - 72.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.